PFS
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
Advertisement
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.